RT Journal Article SR Electronic T1 Role of adjuvant chemoradiotherapy and chemotherapy in patients with resected gallbladder carcinoma: a multi-institutional analysis (KROG 19-04) JF Cancer Biology & Medicine JO Cancer Biology & Medicine FD China Anti-Cancer Association SP 931 OP 944 DO 10.20892/j.issn.2095-3941.2020.0667 VO 19 IS 6 A1 Lee, Sung Uk A1 Seong, Jinsil A1 Kim, Tae Hyun A1 Im, Jung Ho A1 Kim, Woo Chul A1 Kim, Kyubo A1 Park, Hae Jin A1 Kim, Tae Gyu A1 Kim, Youngkyong A1 Jeong, Bae Kwon A1 Kim, Jin Hee A1 Kim, Byoung Hyuck A1 Nam, Taek-Keun YR 2022 UL http://www.cancerbiomed.org/content/19/6/931.abstract AB Objective: The effectiveness of adjuvant treatments for resected gallbladder carcinoma (GBC) has remained unclear due to lack of randomized controlled trials; thus, the aim of present study was to evaluate the role of adjuvant treatments, including chemoradiotherapy (CRT) and/or chemotherapy (CTx), in patients with resected GBC.Methods: A total of 733 GBC patients who received curative-intent surgical resection were identified in a multi-institutional database. Of 733 patients, 372 (50.8%) did not receive adjuvant treatment, whereas 215 (29.3%) and 146 (19.9%) received adjuvant CTx and CRT, respectively. The locoregional recurrence-free survival (LRFS), recurrence-free survival (RFS), and overall survival (OS) of the adjuvant treatment groups were compared according to tumor stage (stage II vs. stage III–IV).Results: In stage II disease (n = 381), the 5-year LRFS, RFS, and OS were not significantly different among the no-adjuvant therapy, CTx, and CRT groups, and positive resection margin, presence of perineural invasion, and Nx classification were consistently associated with worse LRFS, RFS, and OS in the multivariate analysis (P < 0.05). For stage III–IV (n = 352), the CRT group had significantly higher 5-year LRFS, RFS, and OS than the no-adjuvant therapy and CTx groups (67.8%, 45.2%, and 56.9%; 37.9%, 28.8%, and 35.4%; and 45.0%, 30.0%, and 45.7%, respectively) (P < 0.05).Conclusions: CRT has value as adjuvant treatment for resected GBC with stage III–IV disease. Further study is needed for stage II disease with high-risk features.